[Federal Register Volume 86, Number 184 (Monday, September 27, 2021)]
[Notices]
[Pages 53334-53335]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-20908]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of an Exclusive Patent License: Development of 
a Bispecific T Cell Engager for the Treatment and Cure of HIV-1

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The National Cancer Institute, an institute of the National 
Institutes of Health, Department of Health and Human Services, is 
contemplating the grant of an Exclusive Patent License to practice the 
inventions embodied in the Patents and Patent Applications listed in 
the Supplementary Information section of this notice to Gilead 
Sciences, Inc. (``Gilead'') located in Foster City, CA.

DATES: Only written comments and/or applications for a license which 
are received by the National Cancer Institute's Technology Transfer 
Center on or before October 12, 2021 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, 
and comments relating to the contemplated an Exclusive Patent License 
should be directed to: Rose M. Freel, Ph.D., Senior Licensing and 
Patenting Manager, NCI Technology Transfer Center, 8490 Progress Drive, 
Suite 400, Frederick, MD 21701 (for business mail), Telephone: 
(301)624-8775; Email: [email protected].

SUPPLEMENTARY INFORMATION:

Intellectual Property

    United States Provisional Patent Application No. 61/347,088, filed 
May 21, 2010 and entitled ``High-affinity fully functional soluble 
single-domain human CD4, antibodies, and related fusion proteins'' [HHS 
Reference No. E-103-2010/0-US-01];
    PCT Patent Application PCT/US2011/037439, filed May 20, 2011 and 
entitled ``High-affinity fully functional soluble single-domain human 
CD4, antibodies, and related fusion proteins'' [HHS Reference No. E-
103-2010/0-PCT-02];
    United States Patent No. 8,911,728, granted December 16, 2014, 
corresponding to U.S. Application No. 13/699,535, filed January 11, 
2013, entitled ``High-affinity fully functional soluble single-domain 
human CD4, antibodies, and related fusion proteins'' [ HHS Reference 
No. E-103-2010-1-US-03]; and
    European Patent Application No. 21185510.1, filed July 14, 2021, 
entitled ``High-affinity fully functional soluble single-domain human 
CD4, antibodies, and related fusion proteins'' [HHS Reference No. E-
103-2010-1-EP-04].
    The patent rights in these inventions have been assigned and/or 
exclusively licensed to the government of the United States of America.
    The prospective exclusive license territory may be worldwide and 
the field of use may be limited to the use of the Licensed Patent 
Rights for the following: ``For use in an HIV Bispecific T cell engager 
construct comprising the CD4 mD1 which will be utilized in therapeutic 
regimens to treat and cure people living with HIV.''
    This technology discloses highly soluble and stable single-domain 
sCD4 proteins that have therapeutic potential for inhibition of HIV-1 
viral entry into cells. CD4 is a glycoprotein present on the surface of 
mature CD4+ T cells and is the primary receptor allowing the entry of 
HIV-1 into cells. The interaction between the CD4 protein on the cell 
surface and the viral envelope glycoprotein is key for infecting a 
cell. As a result, the single-domain sCD4 proteins described in this 
invention have potential uses in a variety of therapeutic strategies 
attempting to prevent the interaction between cellular CD4 and the 
viral envelope and therefore, inhibition of viral entry.
    This notice is made in accordance with 35 U.S.C. 209 and 37 CFR 
part 404. The prospective exclusive license will be royalty bearing, 
and the prospective exclusive license may be granted unless within 
fifteen (15) days from the date of this published notice, the National 
Cancer Institute receives written evidence and argument that 
establishes that the grant of the license would not be consistent with 
the requirements of 35 U.S.C. 209 and 37 CFR part 404.
    In response to this Notice, the public may file comments or 
objections. Comments and objections, other than those in the form of a 
license application, will not be treated confidentially, and may be 
made publicly available.
    License applications submitted in response to this Notice will be 
presumed to contain business confidential information and any release 
of information in these license applications will be made only as 
required and upon a request under the Freedom of Information Act, 5 
U.S.C. 552.


[[Page 53335]]


    Dated: September 21, 2021.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer 
Institute.
[FR Doc. 2021-20908 Filed 9-24-21; 8:45 am]
BILLING CODE 4140-01-P